FDA Compounding Enforcement Could Have Been More Aggressive, Hamburg Acknowledges; Tense Hearing Continues Legislative Stalemate
This article was originally published in The Pink Sheet Daily
Executive Summary
House Republicans remain unconvinced that FDA needs additional enforcement powers as Commissioner Hamburg is grilled on why the agency didn’t employ its current forceful inspection approach in the run-up to New England Compounding Center tragedy.
You may also be interested in...
FDA Compounder Inspections May Help Set New Enforcement Standard
Agency releases 483 forms from a post-crises inspection push; the effort may help FDA illustrate its inspection capabilities to Congress and states and indicate the agency’s oversight plans under the new authority it has proposed.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
US FDA Hopes Food, Inspection Office Reorg Bolsters Innovative Clinical Trial Adoption
Ensuring inspectors understand the innovative trial designs in use before an inspection will be important to increasing industry confidence in their use, CDER Director Patrizia Cavazzoni said.